Related Experiment Video
Updated: Jan 29, 2026

Reverse Total Shoulder Arthroplasty
Published on: July 5, 2011
Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes
Michael D George1, Joshua F Baker2, Kevin Winthrop3
1University of Pennsylvania Perelman School of Medicine, Philadelphia.
Insights
Withholding abatacept infusions before hip and knee arthroplasty for four weeks or more did not reduce postoperative infection risk. Optimal timing for biologic therapy cessation remains unclear for patients undergoing joint replacement surgery.
Area of Science:
- Rheumatology
- Orthopedic Surgery
- Pharmacology
Background:
- Current guidelines suggest withholding biologic therapies before hip and knee arthroplasty, but evidence for optimal timing is limited.
- Abatacept is a biologic therapy commonly used for rheumatoid arthritis.
Purpose of the Study:
- To investigate whether withholding abatacept infusions before hip and knee arthroplasty is associated with a reduced risk of adverse postoperative outcomes.
- To determine the optimal duration for discontinuing abatacept prior to joint replacement surgery.
Main Methods:
- Retrospective cohort study using US Medicare and Truven MarketScan administrative data (2006-2015).
- Evaluated adults with rheumatoid arthritis receiving intravenous abatacept within 6 months of hip or knee arthroplasty.
- Propensity weighted analyses compared risks of 30-day hospitalized infection, 1-year prosthetic joint infection (PJI), nonurinary infections, and 30-day readmissions based on abatacept cessation timing.
Main Results:
- No significant differences in hospitalized infection, nonurinary hospitalized infection, PJI, or 30-day readmission rates were observed between patients withholding abatacept for <4 weeks versus 4-8 weeks or ≥8 weeks.
- High-dose glucocorticoid use (>7.5 mg/day) was associated with an increased risk of hospitalized and nonurinary hospitalized infections.
Conclusions:
- Withholding abatacept for ≥4 weeks before hip and knee arthroplasty was not associated with a lower risk of postoperative infections or readmissions.
- The optimal timing for discontinuing abatacept infusions before joint replacement surgery requires further investigation.
Objective:
Guidelines recommend withholding biologic therapies before hip and knee arthroplasty, yet evidence to inform optimal timing is limited. The aim of this study was to determine whether withholding abatacept infusions is associated with lower risk of adverse postoperative outcomes.
Methods:
This retrospective cohort study, which used US Medicare and Truven MarketScan administrative data from January 2006 to September 2015, evaluated adults with rheumatoid arthritis who received intravenous abatacept (precisely dated in claims data) within 6 months of elective primary or revision hip or knee arthroplasty. Propensity weighted analyses using inverse probability weights compared the risk of 30-day hospitalized infection and 1-year prosthetic joint infection (PJI) between patients with different abatacept stop timing (time between last infusion and surgery). Secondary analyses evaluated nonurinary hospitalized infections and 30-day readmissions.
Results:
After 1,939 surgeries among 1,780 patients, there were 175 hospitalized infections (9.0%), 115 nonurinary hospitalized infections (5.9%), 39 PJIs (2.4/100 person-years), and 114/1,815 30-day readmissions (6.3%). There were no significant differences in outcomes with abatacept stop timing <4 weeks (1 dosing interval) versus 4-8 weeks (hospitalized infection odds ratio [OR] 0.93 [95% confidence interval (95% CI) 0.65-1.34]; nonurinary hospitalized infection OR 0.93 [95% CI 0.60-1.44]; PJI hazard ratio 1.29 [95% CI 0.62-2.69]; 30-day readmission OR 1.00 [95% CI 0.65-1.54]). Similarly, there were no significant differences in outcomes with abatacept stop timing <4 weeks versus ≥8 weeks. Glucocorticoid use >7.5 mg/day was associated with greater risk of hospitalized infection (OR 2.19 [95% CI 1.28-3.77]) and nonurinary hospitalized infection (OR 2.38 [95% CI 1.22-4.64]).
Conclusion:
Compared to continuing intravenous abatacept, withholding abatacept for ≥4 weeks (one dosing interval) before surgery was not associated with a lower risk of hospitalized infection, nonurinary hospitalized infection, PJI, or 30-day readmission.
Related Concept Videos
Predicting Reaction Outcomes
Relative Risk
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Peripheral Artery Disease V: Postoperative Nursing Management

